Amneal Pharmaceuticals, Inc. (AMRX)

USD 7.69

(-4.71%)

Long Term Debt Summary of Amneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals, Inc.'s latest annual long term debt in 2023 was 2.52 Billion USD , down -7.94% from previous year.
Amneal Pharmaceuticals, Inc.'s latest quarterly long term debt in 2024 Q2 was 2.27 Billion USD , down -10.0% from previous quarter.
Amneal Pharmaceuticals, Inc. reported annual long term debt of 2.74 Billion USD in 2022, down -3.16% from previous year.
Amneal Pharmaceuticals, Inc. reported annual long term debt of 2.83 Billion USD in 2021, down -1.91% from previous year.
Amneal Pharmaceuticals, Inc. reported quarterly long term debt of 2.51 Billion USD for 2024 Q1, down -0.32% from previous quarter.
Amneal Pharmaceuticals, Inc. reported quarterly long term debt of 2.68 Billion USD for 2023 Q3, down -0.37% from previous quarter.

Annual Long Term Debt Chart of Amneal Pharmaceuticals, Inc. (2023 - 2015)

Historical Annual Long Term Debt of Amneal Pharmaceuticals, Inc. (2023 - 2015)

Year	Long Term Debt	Long Term Debt Growth
2023	2.52 Billion USD	-7.94%
2022	2.74 Billion USD	-3.16%
2021	2.83 Billion USD	-1.91%
2020	2.88 Billion USD	5.72%
2019	2.72 Billion USD	2.23%
2018	2.66 Billion USD	91.34%
2017	1.39 Billion USD	20.33%
2016	1.15 Billion USD	21.85%
2015	951.62 Million USD	0.0%

Year	Long Term Debt	Long Term Debt Growth
2024 Q2	2.27 Billion USD	-10.0%
2024 Q1	2.51 Billion USD	-0.32%
2023 Q3	2.68 Billion USD	-0.37%
2023 Q2	2.69 Billion USD	-0.58%
2023 FY	2.52 Billion USD	-7.94%
2023 Q1	2.7 Billion USD	-1.18%
2023 Q4	2.52 Billion USD	-5.94%
2022 Q4	2.74 Billion USD	-0.38%
2022 Q3	2.75 Billion USD	-0.61%
2022 Q2	2.76 Billion USD	-1.85%
2022 FY	2.74 Billion USD	-3.16%
2022 Q1	2.81 Billion USD	-0.36%
2021 Q4	2.83 Billion USD	5.3%
2021 Q1	2.87 Billion USD	-0.26%
2021 Q2	2.87 Billion USD	-0.13%
2021 FY	2.83 Billion USD	-1.91%
2021 Q3	2.68 Billion USD	-6.48%
2020 Q3	2.91 Billion USD	-0.41%
2020 Q1	2.93 Billion USD	7.45%
2020 Q4	2.88 Billion USD	-1.03%
2020 FY	2.88 Billion USD	5.72%
2020 Q2	2.92 Billion USD	-0.18%
2019 Q2	2.74 Billion USD	-0.35%
2019 FY	2.72 Billion USD	2.23%
2019 Q4	2.72 Billion USD	-0.21%
2019 Q3	2.73 Billion USD	-0.35%
2019 Q1	2.75 Billion USD	3.16%
2018 Q4	2.66 Billion USD	-0.2%
2018 FY	2.66 Billion USD	91.34%
2018 Q3	2.67 Billion USD	-0.2%
2018 Q2	2.68 Billion USD	92.54%
2018 Q1	1.39 Billion USD	-0.22%
2017 Q3	1.39 Billion USD	0.0%
2017 Q1	- USD	-100.0%
2017 Q4	1.39 Billion USD	-0.21%
2017 FY	1.39 Billion USD	20.33%
2016 FY	1.15 Billion USD	21.85%
2016 Q4	1.15 Billion USD	0.0%
2015 FY	951.62 Million USD	0.0%

Peer Long Term Debt Comparison of Amneal Pharmaceuticals, Inc.

Name	Long Term Debt	Long Term Debt Difference
Bausch Health Companies Inc.	21.93 Billion USD	88.5%
Catalent, Inc.	4.54 Billion USD	44.491%
Emergent BioSolutions Inc.	446.5 Million USD	-465.039%
Elanco Animal Health Incorporated	5.73 Billion USD	56.016%
Perrigo Company plc	3.63 Billion USD	30.552%
Teva Pharmaceutical Industries Limited	18.48 Billion USD	86.349%
Zoetis Inc.	6.56 Billion USD	61.565%